Get the Stockscreener App
2.885
6.33%
-0.195
Annovis Bio Inc stock is traded at $2.885, with a volume of 581.12K.
It is down -6.33% in the last 24 hours and down -42.87% over the past month.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
See More
Previous Close:
$3.08
Open:
$3.09
24h Volume:
581.12K
Relative Volume:
1.41
Market Cap:
$60.02M
Revenue:
-
Net Income/Loss:
$-40.94M
P/E Ratio:
-0.7513
EPS:
-3.84
Net Cash Flow:
$-22.97M
1W Performance:
-40.76%
1M Performance:
-42.87%
6M Performance:
-64.03%
1Y Performance:
-70.89%
1-Day Range:
$2.88
$3.13
1-Week Range:
$2.88
$4.48
52-Week Range:
$2.88
$20.00
Annovis Bio Inc Stock (ANVS) Company Profile
Name
Annovis Bio Inc
Sector
Industry
Phone
484-875-3192
Address
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
2.885 | 60.02M | 0 | -40.94M | -22.97M | -3.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.24 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.00 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.00 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.48 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.55 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-25-24 | Upgrade | Maxim Group | Hold → Buy |
| Dec-29-23 | Initiated | Canaccord Genuity | Buy |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
Annovis Bio Inc Stock (ANVS) Latest News
Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Annovis Bio CEO to Reveal Critical Alzheimer's Drug Development MilestonesKey Phase 3 Data - StockTitan
Annovis begins treatment of subjects in Alzheimer’s trial - Yahoo Finance
Annovis Bio Raises $21 Million in Public Offering to Advance Alzheimer’s Research - MSN
Annovis Bio announces first patients entered Phase 3 study of buntanetap - Yahoo Finance
Annovis Bio Launches Phase 3 Trial for Alzheimer’s Drug Buntanetap - MyChesCo
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease - GlobeNewswire
Annovis Bio stock hits 52-week low at $4.05 amid market challenges - MSN
Annovis Bio begins pivotal phase 3 Alzheimer's drug trial - MSN
Annovis Bio sets terms for $21 million public offering - MSN
Annovis Bio completes $21 million stock and warrant offering - MSN
Annovis Bio Enrolls First Patients in Phase 3 Trial of Buntanetap for Early Alzheimer's Disease - Marketscreener.com
Annovis Bio begins pivotal phase 3 Alzheimer's drug trial By Investing.com - Investing.com South Africa
Annovis Bio Launches Phase 3 Alzheimer’s Study - TipRanks
Major Alzheimer's Breakthrough: First Patients Begin Treatment in Groundbreaking Phase 3 Trial - StockTitan
Annovis Bio completes $21 million stock and warrant offering By Investing.com - Investing.com South Africa
Annovis Bio, Inc. Announces Closing of $21 Million Public Offering - GlobeNewswire
Alzheimer's Drug Developer Annovis Secures Critical $21M Funding for Final-Stage Trial - StockTitan
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Annovis Bio stock dips after pricing $21M securities offering - MSN
Annovis Bio Prices $21 Million Public Offering; Shares Fall Sharply -February 03, 2025 at 11:56 am EST - Marketscreener.com
Annovis Bio sets terms for $21 million public offering By Investing.com - Investing.com Australia
Annovis Bio announces pricing of $21M offering of stock, warrants - TipRanks
Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering - GlobeNewswire
Annovis Bio Secures Critical $21M Funding: Major Push for Breakthrough Buntanetap Drug Development - StockTitan
Annovis Bio Announces Public Offering of Common Stock and Warrants - MSN
Major Funding Push: Annovis Bio's Next Move in Revolutionary Alzheimer's Treatment Race - StockTitan
Annovis Bio, Inc. Announces Proposed Public Offering - The Bakersfield Californian
Alterity Therapeutics announces ATH434 Phase 2 trial results - MSN
Annovis Bio Secures U.S. Patent for Neuroprotective Drug Buntanetap - MSN
What's Going With Annovis Bio Shares Tuesday? - MSN
Bay Area biotech firm Allakos suddenly on brink of collapse after trial flops - MSN
Why Intuitive Surgical Stock Was Pulling Back Today - The Globe and Mail
Annovis Bio, Inc. (NYSE:ANVS) Shares Purchased by Merit Financial Group LLC - Defense World
Merit Financial Group LLC Has $496,000 Holdings in Annovis Bio, Inc. (NYSE:ANVS) - MarketBeat
Parkinson's Disease Clinical and Non-Clinical Studies, Key - openPR
Annovis Bio granted U.S. patent covering buntanetap - Yahoo Finance
Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection - GlobeNewswire
Annovis Bio secures US patent for brain injury treatment By Investing.com - Investing.com Nigeria
Annovis Bio secures US patent for brain injury treatment - Investing.com India
Annovis Bio Secures Key U.S. Patent for Brain Injury Treatment Breakthrough Buntanetap - StockTitan
Passage Bio Reports Promising Data in Trial for Frontotemporal Dementia Treatment - MyChesCo
Geode Capital Management LLC Has $799,000 Position in Annovis Bio, Inc. (NYSE:ANVS) - Defense World
Annovis Bio, Inc. (NYSE:ANVS) Given Average Rating of “Buy” by Analysts - Defense World
Annovis Bio, Inc. (NYSE:ANVS) Receives $31.40 Average Price Target from Analysts - MarketBeat
Annovis Bio Stock Among Retail's Top Draws After FDA Nod For Final Phase 3 Alzheimer’s Study Protocol - MSN
Annovis Bio Inc Stock (ANVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):